Glenmark’s blood cancer drug ISB 2001 shows promising results in trial

Ichnos Glenmark Innovation's ISB 2001 has shown promising results in treating relapsed or refractory multiple myeloma (RRMM), demonstrating a 79% overall response rate in a Phase 1 study. The drug targets two sites on the tumor cell and engages the body's T-cells, offering hope for patients who have exhausted other treatment options.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xBID9qW
via IFTTT